Regeneron Pharmaceuticals (REGN)

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the industry’s returns - over the past six months, healthcare stocks have collectively shed 8.4%. This drop is a stark contrast from the S&P 500’s 5.4% gain.

Donald Trump's proposed 200% tariffs can squeeze the profit margins of pharma companies, but LLY is poised to "benefit" except for the rest.

Companies with more cash than debt can be financially resilient, but that doesn’t mean they’re all strong investments. Some lack leverage because they struggle to grow or generate consistent profits, making them unattractive borrowers.

A U.S. bankruptcy judge ruled that California's appeal to block the deal was unlikely to succeed, rejecting claims that the sale violated state genetic privacy laws.

Apogee Therapeutics shares crumbled Monday despite promising results for what could become a twice-yearly eczema shot.

REGENERON PHARMACEUTICALS (NASDAQ:REGN) offers strong profitability, financial health, and an attractive valuation, making it a potential pick for value investors in the biotech sector.

FDA grants accelerated approval to Regeneron's Lynozyfic for relapsed multiple myeloma after strong results in a Phase 1/2 trial.

While Lynozyfic was granted accelerated approval based on response rate in the LINKER-MM1 trial, continued approval may depend upon verification and description of clinical benefit in a confirmatory trial, the company said.

Nektar Therapeutics soared 157% after Rezpeg succeeded in a Phase 2b eczema trial. Analysts forecast huge upside—here’s why there could be more gains ahead.

While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifies - as Jeff Bezos said, "Your margin is my opportunity".

Nektar's rezpegaldesleukin met key efficacy targets in a mid-stage eczema study, though analysts flagged safety and differentiation concerns.

Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look at Regeneron (NASDAQ:REGN) and its peers.

Dupixent approved by FDA for bullous pemphigoid, offering a new option for adults with the rare autoimmune skin disease following positive trial results.

The injection is now approved in the U.S. to treat eight distinct diseases with underlying type 2 inflammation.

Apitegromab therapy with Tirzepatide preserved an additional 4.2 pounds of lean mass compared to Tirzepatide alone in the study, the company said.

Scholar Rock's apitegromab helped preserve muscle mass during tirzepatide-induced weight loss, improving overall body composition in Phase 2 trial.

These two S&P 500 stocks, which fell between 18.2% and 26.6% in May, are worth watching.

Think every Nasdaq-100 stock was a winner last month? The numbers might surprise you.

Novo Nordisk and Deep Apple ink a deal to develop oral therapies targeting a novel GPCR for cardiometabolic diseases, including obesity.